StreetInsider.com News Articles

Oppenheimer on Gain Therapeutics (GANX): 'Ph2a study initiation remains on track for 3Q26'

Wed, 27 May 2026 04:28:41 -0400

Oppenheimer analyst Jay Olson reiterated an Outperform rating and $8.00 price target on Gain Therapeutics (NASDAQ: GANX).

The analyst comments "GANX reported additional interim Ph1b data at GBA1 with incremental follow-up as all 16/16 Part-2 patients have completed 5-months of dosing (compared to 14/16 as of last March-2026 cutoff). In summary, we see these interim data teeing up an interesting topline Ph1b readout in October, given: 1) the Day-150 MDS-UPDRS breakdown by baseline GluSph follows the same trend observed at Day-90: patients with higher baseline GluSph appear to benefit more; and 2) overall MDS-UPDRS trends over time remain consistent with prior

Form 8-K Gain Therapeutics, Inc. For: May 26

Tue, 26 May 2026 09:26:00 -0400

si-local-file:///var/storage/secattach/20260526/26547032.html

Form 8-K Gain Therapeutics, Inc. For: May 26

Tue, 26 May 2026 09:26:00 -0400

si-local-file:///var/storage/secattach/20260526/26547032.html

Gain Therapeutics reports interim data from Parkinson's disease study

Tue, 26 May 2026 08:01:19 -0400

Gain Therapeutics Inc. (NASDAQ: GANX) presented interim data from its Phase 1b clinical study of GT-02287 for Parkinson's disease at the 3rd International GBA1 Meeting held May 22-23, 2026, in Phoenix, Arizona.

The company reported that MDS-UPDRS scores remained stable across the overall study population after 150 days of treatment with GT-02287. The study showed a differential response between participants with low and high baseline glucosylsphingosine (GluSph) levels, with a 4.8-point difference in combined MDS-UPDRS Part II and Part III scores between the two groups at day 150.

Study participants reported improvements in smell and taste, sleep, and balance or gait. The

Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026

Tue, 26 May 2026 08:00:00 -0400

MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treatment with GT-02287

Differential response between participants with low and high baseline GluSph continues, with a difference of 4.8 points in the sum of MDS-UPDRS Part II and Part III scores between the two groups at Day 150

Most common benefits reported by study participants include meaningful improvements in specific functional areas such as smell and taste, sleep, and balance or gait

BETHESDA, Md., May 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the

Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026

Tue, 26 May 2026 08:00:00 -0400

MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treatment with GT-02287

Most common benefits reported by study participants include meaningful improvements in specific functional areas such as smell and taste, sleep, and balance or gait

BETHESDA, Md., May 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the

Form 10-Q Gain Therapeutics, Inc. For: Mar 31

Mon, 11 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260511/26469079.html

Form 10-Q Gain Therapeutics, Inc. For: Mar 31

Mon, 11 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260511/26469079.html

Form 8-K Gain Therapeutics, Inc. For: May 11

Mon, 11 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260511/26468960.html

Form 8-K Gain Therapeutics, Inc. For: May 11

Mon, 11 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260511/26468960.html

Gain Therapeutics, Inc. (GANX) Tops Q1 EPS by 1c

Mon, 11 May 2026 07:22:11 -0400

Gain Therapeutics, Inc. (NASDAQ: GANX) reported Q1 EPS of ($0.13), $0.01 better than the analyst estimate of ($0.14).

For earnings history and earnings-related data on Gain Therapeutics, Inc. (GANX) click here.

Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update